Gleamer secures €27 million in series B funding to advance AI-driven radiology care

Gleamer, a trailblazing company specializing in AI-powered medical imaging solutions, has achieved a significant milestone with the successful completion of its Series B financing round, securing an impressive €27 million in funding. This achievement propels Gleamer into a new chapter of its mission to revolutionize healthcare through cutting-edge technology.

Supernova Invest, a leading investment firm, spearheaded the funding round, with co-leader Heal Capital and the continued support of Gleamer’s long-term partners, including XAnge, Elaia, Bpi France, MACSF, UI Investissement, and Crista Galli Ventures, as well as numerous European radiologists. With a cumulative funding of €35.5 million to date, Gleamer is poised to expand its solutions portfolio, bolster its teams in Europe and America, and accelerate its international expansion plans.

Since its establishment in 2017, Gleamer has established itself as a frontrunner in AI-driven medical imaging solutions. Its comprehensive suite of clinical diagnostic solutions, powered by AI technology, has earned certification as a Class IIa medical device under EU MDR and has achieved partial FDA clearance. The company’s solutions have gained worldwide renown, with nine publications in major medical journals and recognition from the scientific community.

Currently, Gleamer serves over 6,500 users in 650 institutions across 24 countries, processing over a million medical examinations each month. The recent influx of funding will empower Gleamer to bring its strategic roadmap to fruition, deploy disruptive technological solutions at scale, and cater to the evolving needs of healthcare professionals worldwide.

Christian Allouche, CEO and co-founder of Gleamer, expressed his excitement about the new funding round, emphasizing the company’s commitment to making AI the new standard of care in radiology. Allouche stated, “We aim to increase diagnostic accuracy and improve patient care and the efficiency of clinical practices for health professionals.”

Looking ahead, Gleamer has set its sights on expanding its solutions portfolio to include CT scans and mammography, effectively covering 70% of radiologists’ routine needs. The company plans to accelerate its international expansion, with a particular focus on Europe and the United States, by strengthening its sales teams and forging strategic partnerships. These partnerships will facilitate the reach of Gleamer’s innovative solutions to a broader audience, ultimately benefiting countless individuals.

Rémi Spagnol, Investment Director at Supernova Invest, remarked, “Gleamer is positioned as a leader in the use of AI in radiology, redefining the contours of radiology and medical imaging through disruptive technology solutions that can be deployed on a large scale.”

Gleamer’s remarkable growth and exceptional performance have earned them the esteemed title of EuroMinnies 2023 Best Vendor in Radiology, as awarded by AuntMinnie Europe.

At Gleamer, the team firmly believes that AI represents the new standard of care in radiology. They express gratitude for the support of their investors, who share their vision for the future of healthcare. Together, they are determined to push boundaries, drive innovation, and make a positive impact on patients’ lives worldwide.